Martorell no.124 08740 Sant Andreu de la Barca Spain Scope Category I Production of customer specific Masterbatches for Food packaging materials on the dedicated extrusion lines Normative base ISO 22000:2018 Food Safety Management Systems Requirements for any organization in the food chain Reg. no. 46388 Validity 25. 02. 2021 – 24. 02. 2024 Issue 25. 02. 2021 Swiss Madesqs.ch F.

Nilai-nilai ini membentuk komitmen yang kita lakukan sebagai karyawan Avient terhadap satu sama lain, kepada para pemangku kepentingan, dan masyarakat kita. PEDOMAN PERILAKU | 24 DAFTAR ISI PERKENALAN PEDOMAN PERILAKU KITA MENGHORMATI SEMUA ORANG KEJUJURAN DI TEMPAT KERJA INTEGRITAS DALAM BISNIS KITA TANGGUNG JAWAB SOSIAL PERUSAHAAN SUMBER DAYA https://secure.ethicspoint.com/domain/media/en/gui/49178/index.html Transaksi Mandiri Peluang bisnis yang Anda temukan di tempat kerja, menggunakan informasi Perusahaan, properti, atau jabatan seseorang di Perusahaan, menjadi milik Perusahaan dan bukan milik Anda secara pribadi. Francisco Nakasato, 1700 13295-000 Itupeva Sao Paulo, Brasil Telepon: +55 11 4593 9200 Eropa Regional Headquarters Pommerloch, Luksemburg 19 Route de Bastogne Pommerloch, Luksemburg, L-9638 Telepon: +352 269 050 35 Faks: +352 269 050 45 www.avient.com http://www.avient.com Pernyataan kepatuhan terhadap pedoman perilaku avient Petunjuk: Baca, tanda tangani, dan kembalikanlah dokumen ini ke bagian Sumber Daya Manusia.

TEMPERATURE, MPa Temperature (C) Fl ex ur al S tr en gt h (M Pa ) Fl ex ur al M od ul us (G Pa ) 20 25 30 35 40 Glass/Epoxy High Temp Glass/Vinyl ester 1409040-10-60 0 300 600 900 1200 1500 Glass/Epoxy High Temp Epoxy/Glass Glass/Vinyl Ester 1901409040-10-60 200 400 600 800 1000 1200 14801280108088068048028080 FLEXURAL MODULUS VS. TEMPERATURE, GPa Temperature (C) 20 25 30 35 40 Glass/Epoxy High Temp Glass/Vinyl ester 1409040-10-60 0 300 600 900 1200 1500 Glass/Epoxy High Temp Epoxy/Glass Glass/Vinyl Ester 1901409040-10-60 200 400 600 800 1000 1200 14801280108088068048028080 FLEXURAL FATIGUE STRENGTH, MPa Cycles to Failure (in thousands) Fl ex ur al F at iq ue S tr en gt h (M Pa ) INSTALLATION INSTRUCTIONS Proper installation of composite springs from Avient is essential to achieve optimal performance and maximum service life.

They pass EN 50618 and IEC 60332-1 standards on the assembled cable (if the cable jacketing and insulation are both produced with ECCOH XL 8148 solutions).

Cesa Stat Antistatic Additives for automotive can support customers with electrostatic decay time testing according to Standard DIN EN 61340-2-1 to speed up the development.

KEY BENEFITS • EPBP bottle-to-bottle recyclability accredited • Non-nylon based product • Compatible with rPET (recommended for >up to 100% rPET content) • No scavenging delay or deactivation • Excellent bottle clarity • Fit to use in monolayer as well as multi-layer bottle structures * European Platform for Bottle Packaging 1 https://eur-lex.europa.eu/legal-content/EN/ LSU/?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 24 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 3 3 3 4 3 3 4 4 4 5 5 5 5 7 7 8 23 A vi en t A vi en t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of March 12, 2021 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of March 12, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 26 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 11.3 18.6 14.3 13.6 13.3 12.2 10.7 28.8 26.3 23.3 14.6 12.4 11.7 11.6 11.2 11.0 10.6 10.3 9.6 9.1 8.5 7.2 A vi en t K W R A V Y R P M P P G G C P F U L H X L A L B E C L IF F F M C A S H F O E B N R C E G R A E M N S C L U N V R K R A H U N Median: 11.2xMedian: 13.5x SUMMARY: WHY INVEST IN AVIENT?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 18 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 4 3 3 3 4 4 5 5 5 6 7 7 8 24 A vi en t A vi en t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?

OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi en t (2 01 1) A vi en t (2 01 6) A vi en t (2 02 1) A vi en t (T o da y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple SUMMARY: WHY INVEST IN AVIENT?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 6 2 3 4 4 5 5 5 6 6 6 7 9 25 A vi en t A vi en t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi en t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 A vi en t K W R A V Y R P M G C P P P G F U L A L B E C L H X L IF F F M C G R A B N R F O E A S H C E S C L U N V R E M N H U N K R A Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT?